Trials / Unknown
UnknownNCT01991301
Carfilzomib for the Prevention of Graft Versus Host Disease
The Safety and Efficacy of Carfilzomib -a Novel Proteasome Inhibitor- for the Prevention of Acute Graft Versus Host Disease
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Sheba Medical Center · Other Government
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to evaluate the safety and efficacy of Carfilzumib, which is a novel biological agent used in the treatment of multiple myeloma in preventing graft-versus-host disease, after stem cells transplantation from unrelated donors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | carfilzumib | carfilzumib will be added to the standard regimen of drugs for prevention of graft-versus-host disease. |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2017-11-01
- Completion
- 2017-11-01
- First posted
- 2013-11-25
- Last updated
- 2015-12-02
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT01991301. Inclusion in this directory is not an endorsement.